ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 90 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2020. The put-call ratio across all filers is 0.71 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,517 | -3.3% | 3,441 | +51.3% | 0.00% | 0.0% |
| Q2 2023 | $17,085 | +27456.5% | 2,275 | -83.4% | 0.00% | -50.0% |
| Q1 2023 | $62 | +376.9% | 13,694 | +1021.5% | 0.00% | +100.0% |
| Q4 2022 | $13 | -100.0% | 1,221 | -86.7% | 0.00% | 0.0% |
| Q3 2022 | $88,000 | +54.4% | 9,200 | +29.8% | 0.00% | 0.0% |
| Q2 2022 | $57,000 | +18.8% | 7,090 | +147.6% | 0.00% | – |
| Q1 2022 | $48,000 | -47.8% | 2,864 | -33.0% | 0.00% | -100.0% |
| Q4 2021 | $92,000 | -12.4% | 4,277 | +200.1% | 0.00% | -33.3% |
| Q3 2021 | $105,000 | +18.0% | 1,425 | -12.6% | 0.00% | +50.0% |
| Q2 2021 | $89,000 | +58.9% | 1,630 | +114.2% | 0.00% | +100.0% |
| Q1 2021 | $56,000 | -52.5% | 761 | -44.6% | 0.00% | -75.0% |
| Q4 2020 | $118,000 | +96.7% | 1,373 | -13.3% | 0.00% | +300.0% |
| Q3 2020 | $60,000 | – | 1,583 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |